Jasbir Seehra - Apr 4, 2025 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Keith Regnante, Attorney-in-Fact
Stock symbol
KROS
Transactions as of
Apr 4, 2025
Transactions value $
$14,810
Form type
4
Date filed
4/7/2025, 04:15 PM
Previous filing
Feb 23, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Options Exercise $14.8K +49.4K +19.52% $0.30 302K Apr 4, 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -49.4K -16.36% $0.00 252K Apr 4, 2025 Common Stock 49.4K $0.30 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Immediately exercisable.